Exencial Wealth Advisors LLC Sells 6,168 Shares of Pfizer Inc. $PFE

Exencial Wealth Advisors LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 8.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,548 shares of the biopharmaceutical company’s stock after selling 6,168 shares during the period. Exencial Wealth Advisors LLC’s holdings in Pfizer were worth $1,710,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Citizens & Northern Corp boosted its stake in shares of Pfizer by 35.0% in the second quarter. Citizens & Northern Corp now owns 49,935 shares of the biopharmaceutical company’s stock valued at $1,210,000 after buying an additional 12,934 shares during the period. FNY Investment Advisers LLC boosted its stake in shares of Pfizer by 61.6% in the second quarter. FNY Investment Advisers LLC now owns 27,324 shares of the biopharmaceutical company’s stock valued at $662,000 after buying an additional 10,414 shares during the period. Studio Investment Management LLC boosted its stake in shares of Pfizer by 22.8% in the second quarter. Studio Investment Management LLC now owns 30,099 shares of the biopharmaceutical company’s stock valued at $730,000 after buying an additional 5,595 shares during the period. Schulhoff & Co. Inc. boosted its stake in shares of Pfizer by 7.0% in the second quarter. Schulhoff & Co. Inc. now owns 49,411 shares of the biopharmaceutical company’s stock valued at $1,198,000 after buying an additional 3,213 shares during the period. Finally, D.A. Davidson & CO. boosted its stake in shares of Pfizer by 58.3% in the second quarter. D.A. Davidson & CO. now owns 3,068,515 shares of the biopharmaceutical company’s stock valued at $74,381,000 after buying an additional 1,130,014 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several recent research reports. Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, UBS Group restated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.13.

Pfizer Stock Down 0.5%

NYSE PFE opened at $24.72 on Thursday. The business has a fifty day moving average price of $24.88 and a two-hundred day moving average price of $24.13. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.17. The stock has a market capitalization of $140.52 billion, a PE ratio of 13.15, a PEG ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.